GENE ONLINE|News &
Opinion
Blog

2021-08-31| Trials & Approvals

Poseida Presents Encouraging Preliminary Data for Autologous CAR-T Candidate Against Solid Tumors

by Rajaneesh K. Gopinath
Share To
Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said, “Other CAR-T products have not had much success against solid tumors. They have been very successful for liquid tumors, but not outside of it. We are very excited because these results are encouraging not just from the perspective of mCRPC patients or anti-PSMA therapeutics but for CAR-T products, in general, against solid tumors. These are among the best responses ever seen.”

"This innovative Poseida PSMA-directed CAR T cell platform has demonstrated a robust anti-tumor response in patients with metastatic castration resistant prostate cancer” commented Susan F. Slovin, M.D., Ph.D., Associate Vice Chair of Academic Administration at Memorial Sloan Kettering Cancer Center, and investigator on the trial. “This is the first time that I have seen such impressive responses with an immunotherapy product. The responses of my patients in the trial are far beyond my expectations.”

GO Prime with only $1.49 now

LATEST
AZ, Merck’s PARP Inhibitor Shines in Phase 3 Prostate Cancer Trial
2021-09-26
How Patients with dMMR/MSI-H Tumors Can Benefit from Immunotherapy?
2021-09-24
Foxconn Subsidiary Invests $90.8 Million in Taiwanese CDMO, EirGenix
2021-09-24
China Drugmaker Aims for First Generic Drug Approval of Novartis’ Tasigna in China
2021-09-24
FDA Approves Incyte’s Jakafi for Chronic Graft-Versus-Host Disease
2021-09-23
858 Therapeutics Launches with $60 Million Series A for Advancing Small-Molecule Drugs
2021-09-23
New Study Supports Llama Nanobodies As Potential COVID-19 Treatment
2021-09-23
EVENT
2021-09-28
Cell & Gene Therapy USA
Virtual
2021-10-05
BioFuture
New York City, USA
2021-10-13
BioJapan / Regenerative Medicine Japan / healthTECH JAPAN 2021
Yokohama, Japan & Online Partnering
2021-10-25
AusBiotech 2021
Online and on-demand
Scroll to Top

Subscribe To Our News

Keep yourself updated at all times!

Create an account with us now to say goodbye to all the pop-ups!